NeoPharm Will Not Face SEC Charges
The SEC’s formal investigation, which began in March 2004, concerned allegedly misleading public statements the company made regarding the development of its liposome-encapsulated paclitaxel and liposome-encapsulated doxorubicin products, NeoPharm said.
As a result of the alleged misleading statements, a class action lawsuit was filed against the company at about that time.
Additionally, Waukegan, Ill.-based NeoPharm had sued Pharmacia...
To view the full article, register now.